Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + SBRT Neoadjuvant for HCC with PVTT
NCT06664996Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2024
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in hepatocellular carcinoma (HCC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Disease-Free Survival at 1 year. Started Oct 2024; status: recruiting.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06664996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06664996.